Sun Pharmaceutical Industries Ltd reported a strong set of Q4FY26 results, driven by healthy growth in its innovative medicines portfolio and steady expansion across global markets.
For the quarter ended March 31, 2026, the company reported consolidated sales of ₹14,559.8 crore, registering a 13.6% year-on-year growth.
Net profit for the quarter rose 26.2% YoY to ₹2,714 crore, while EBITDA increased 6.4% to ₹3,954.2 crore. EBITDA margin for Q4FY26 stood at 27.1%.
Sun Pharma said its Global Innovative Medicines business reported sales of US$354 million during the quarter. Sales from the innovative medicines segment grew 20.1% year-on-year and accounted for 22.2% of overall sales during Q4FY26.
The company has renamed its specialty business as the “innovative medicines” business, reflecting its increasing focus on differentiated and specialty-led therapies across global markets.
Research and development investment during the quarter stood at ₹975.7 crore, equivalent to 6.7% of sales.
Sun Pharma remains India’s largest pharmaceutical company and has a strong global presence across branded formulations, generics, specialty therapies and active pharmaceutical ingredients.
Disclaimer: This article is based on company-reported financial results and filings. Investors are advised to consult certified financial advisors before making investment decisions.